Viking TherapeuticsVKTX
VKTX
About: Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Employees: 49
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
131% more call options, than puts
Call options by funds: $222M | Put options by funds: $96M
58% more repeat investments, than reductions
Existing positions increased: 158 | Existing positions reduced: 100
5.73% less ownership
Funds ownership: 73.6% [Q4 2024] → 67.87% (-5.73%) [Q1 2025]
9% less funds holding
Funds holding: 407 [Q4 2024] → 369 (-38) [Q1 2025]
34% less first-time investments, than exits
New positions opened: 66 | Existing positions closed: 100
44% less capital invested
Capital invested by funds: $3.3B [Q4 2024] → $1.84B (-$1.46B) [Q1 2025]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$38
13%
upside
Avg. target
$87
159%
upside
High target
$122
262%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Raymond James Ryan Deschner | 262%upside $122 | Strong Buy Maintained | 24 Jul 2025 |
Citigroup David Lebowitz | 13%upside $38 | Neutral Maintained | 24 Jul 2025 |
HC Wainwright & Co. Joseph Pantginis | 203%upside $102 | Buy Reiterated | 25 Jun 2025 |
Financial journalist opinion
Based on 24 articles about VKTX published over the past 30 days
Positive
Seeking Alpha
5 days ago
Viking Therapeutics Q2: Confidently Continuing The Recovery
Viking Therapeutics' stock has outperformed the S&P 500 since its April lows, marking a solid turnaround. The company's dual-track approach (injectables and oral) for VK2735 positions it well against leaders Eli Lilly and Novo Nordisk, as recent results show solid progress. Strong liquidity position provides a reasonable cash runway through 2027, supporting R&D initiatives and upcoming key clinical data releases.
Negative
Zacks Investment Research
6 days ago
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
Shares of Viking slide after Q2 loss widens to 58 cents per share on rising R&D and nil revenues, missing estimates by 14 cents.
Neutral
Seeking Alpha
6 days ago
Viking Therapeutics, Inc. (VKTX) Q2 2025 Earnings Call Transcript
Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q2 2025 Earnings Conference Call July 23, 2025 4:30 PM ET Company Participants Brian Lian - President, CEO & Director Gregory Zante - Chief Financial Officer Conference Call Participants Stephanie Diaz - Vida Strategic Partners, Inc. Ryan Deschner - Raymond James & Associates, Inc., Research Division Joon Lee - Truist Securities, Inc., Research Division Mayank Mamtani - B. Riley Securities, Inc., Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Hardik Parikh - JPMorgan Chase & Co, Research Division Michael Ulz - Morgan Stanley, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Jiale Song - Jefferies LLC, Research Division Biren Amin - Piper Sandler & Co., Research Division Tsan-Yu Hsieh - William Blair & Company L.L.C.
Negative
The Motley Fool
1 week ago
Viking Therapeutics Posts Wider Q2 Loss
Viking Therapeutics Posts Wider Q2 Loss
Neutral
PRNewsWire
1 week ago
Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today Phase 3 VANQUISH Registration Trials Underway for VK2735 in Obesity Phase 2 VENTURE-Oral Dosing Trial Enrollment Completed; Top-Line Results Expected 2H25 Continued Progress with Amylin Program; IND Planned 4Q25 Strong Quarter-End Cash Position of $808 Million SAN DIEGO , July 23, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2025, and provided an update on its clinical pipeline and other corporate developments.
Positive
The Motley Fool
1 week ago
Better Growth Buy: Eli Lilly vs. Viking Therapeutics
Eli Lilly (LLY -1.24%) and Viking Therapeutics (VKTX -0.12%) have garnered considerable attention over the past year due to their solid clinical progress. However, these drugmakers have also lagged the market over the trailing-12-month period.
Positive
Zacks Investment Research
1 week ago
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
With no revenue expected, VKTX's Q2 report is likely to have the spotlight on pipeline moves across its obesity drugs.
Positive
The Motley Fool
1 week ago
3 Monster Stocks in the Making to Buy Right Now
Where can you find the next monster stocks? Check out the biotech space.
Positive
The Motley Fool
1 week ago
These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy?
Investors seeking stocks that can put up dramatic gains in a short amount of time can find what they're looking for in the biotechnology industry. Investment bank analysts on Wall Street have tagged a pair of pre-revenue businesses with price targets that are miles above their current stock prices.
Neutral
The Motley Fool
1 week ago
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.
Any investor who owned Viking Therapeutics (VKTX -0.23%) before November of last year is sure to be disappointed and maybe even a little worried. Shares are down nearly 60% since October last year and lower to the tune of 68% from their early 2024 high after soaring in 2023.
Charts implemented using Lightweight Charts™